PPD, Inc. Honored For Patient-Centric Communications On Clinical Research

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has won recognition for a patient-centered communications campaign demonstrating the company’s commitment to helping biopharmaceutical clients deliver life-changing medical treatments.

“At PPD, we are both professionally and personally motivated to help our clients in the search for new medicines”

PPD received a Ragan Employee Communications Award for best article series for a collection of stories highlighting employees’ personal experiences with clinical trials. The series, titled “It’s Personal to Us,” featured monthly stories highlighting PPD employees who have participated in clinical trials. The campaign’s goal was to motivate employees by sharing the personal stories of struggle, hope and triumph that their colleagues had experienced, further engaging a workforce already passionately committed to finding life-saving medicines.

“At PPD, we are both professionally and personally motivated to help our clients in the search for new medicines,” said Elizabeth Kuronen, vice president of strategic communications and marketing for PPD. “Understanding the patient’s perspective is incredibly important in recruiting trial participants and for effective clinical trial design and conduct. The voices of our employees and their inspiring stories help reinforce our commitment to our ultimate goal of improving health and saving lives.”

The “It’s Personal to Us” series generated such strong readership metrics and positive feedback from employees around the globe that the company created an external campaign that demonstrates PPD employees’ commitment to clinical trials. PPD debuts these stories publicly April 22-24, at the Partnerships in Clinical Trials conference, at booth 100, in Boston, Massachusetts, to help raise awareness and funds for JDRF, Rock CF and the American Cancer Society.

PPD also spotlights the importance of patient-centricity in clinical trials through its annual PPD Hero campaign during the PPD Beach2Battleship Triathlon. PPD Heroes, everyday people who have overcome illness with medical treatments developed through clinical research, compete in the triathlon and raise awareness about the importance of increasing participation in clinical trials.

PPD received the Ragan Employee Communications Award earlier this month. Ragan Communications is a leading publisher of corporate communications, public relations, and leadership development newsletters and provides professional communicators and executives with timely, practical, and relevant information in the areas of employee communication, organizational writing and editing, sales and marketing, media relations and motivational management.

About PPD

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning communications campaigns contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.